Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models

被引：0
作者：
Christian Lehmann
Thomas Friess
Fabian Birzele
Anna Kiialainen
Markus Dangl
机构：
[1] Roche Pharma Research & Early Development,
[2] Roche Innovation Center Munich,undefined
[3] Roche Diagnostics GmbH,undefined
[4] Roche Pharma Research & Early Development,undefined
[5] Roche Innovation Center Basel,undefined
[6] F-Hoffmann-La Roche Ltd,undefined
[7] Present address: Medigene Immunotherapies GmbH,undefined
来源：
Journal of Hematology & Oncology | / 9卷
关键词：
BCL-2; MDM2; AML; Cell cycle kinetics; Apoptosis; Idasanutlin; Venetoclax; p53; MCL-1; Synergism;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Targeting PSMA7 in combination with RT and MDM2 inhibition enhances cell death in p53 wild-type GBM
    Showalter, Christian A.
    Rajasekera, Priyani V.
    Manring, Heather R.
    Haque, Saikh J.
    Chakravarti, Arnab
    RADIOTHERAPY AND ONCOLOGY, 2024, 194 : S5333 - S5334
  • [42] Therapeutic synergy of Triptolide and MDM2 inhibitor against acute myeloid leukemia through modulation of p53-dependent and -independent pathways
    Chen, Qinwei
    Deng, Suqi
    Deng, Manman
    Shi, Yuanfei
    Zhong, Mengya
    Ding, Lihong
    Jiang, Yuelong
    Zhou, Yong
    Carter, Bing Z.
    Xu, Bing
    EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2022, 11 (01)
  • [43] Therapeutic synergy of Triptolide and MDM2 inhibitor against acute myeloid leukemia through modulation of p53-dependent and -independent pathways
    Qinwei Chen
    Suqi Deng
    Manman Deng
    Yuanfei Shi
    Mengya Zhong
    Lihong Ding
    Yuelong Jiang
    Yong Zhou
    Bing Z. Carter
    Bing Xu
    Experimental Hematology & Oncology, 11
  • [44] Expression of wild-type p53 and bcl-2 family genes oscillates with recurrent remission and relapse in an unusual case of low-grade lymphoma
    Aizman, I
    Many, A
    Peller, S
    Ramot, B
    Kaufmann, Y
    ACTA HAEMATOLOGICA, 2000, 103 (04) : 177 - 185
  • [45] Tumor proliferative compartment, multidrug resistance gene product and apoptosis regulatory p53 and bcl-2 proteins in pediatric acute lymphoblastic leukemia
    Srinivas, G
    Kusumakumari, P
    Nair, MK
    Panicker, KR
    Pillai, MR
    ONCOLOGY REPORTS, 1997, 4 (05) : 1083 - 1087
  • [46] Synergistic effects of p53 activation via MDM2 inhibition in combination with inhibition of Bcl-2 or Bcr-Abl in CD34+ proliferating and quiescent chronic myeloid leukemia blast crisis cells
    Carter, Bing Z.
    Mak, Po Yee
    Mak, Duncan H.
    Ruvolo, Vivian R.
    Schober, Wendy
    McQueen, Teresa
    Cortes, Jorge
    Kantarjian, Hagop M.
    Champlin, Richard E.
    Konopleva, Marina
    Andreeff, Michael
    ONCOTARGET, 2015, 6 (31) : 30487 - 30499
  • [47] The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia
    Willems, L.
    Chapuis, N.
    Puissant, A.
    Maciel, T. T.
    Green, A. S.
    Jacque, N.
    Vignon, C.
    Park, S.
    Guichard, S.
    Herault, O.
    Fricot, A.
    Hermine, O.
    Moura, I. C.
    Auberger, P.
    Ifrah, N.
    Dreyfus, F.
    Bonnet, D.
    Lacombe, C.
    Mayeux, P.
    Bouscary, D.
    Tamburini, J.
    LEUKEMIA, 2012, 26 (06) : 1195 - 1202
  • [48] The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia
    L Willems
    N Chapuis
    A Puissant
    T T Maciel
    A S Green
    N Jacque
    C Vignon
    S Park
    S Guichard
    O Herault
    A Fricot
    O Hermine
    I C Moura
    P Auberger
    N Ifrah
    F Dreyfus
    D Bonnet
    C Lacombe
    P Mayeux
    D Bouscary
    J Tamburini
    Leukemia, 2012, 26 : 1195 - 1202
  • [49] Modulation of wild-type p53 activity by mutant p53 R273H depends on the p53 responsive element (p53RE).: A comparative study between the p53REs of the MDM2, WAFI/Cip1 and Bax genes in the lung cancer environment
    Zacharatos, PV
    Gorgoulis, VG
    Kotsinas, A
    Manolis, EN
    Liloglou, T
    Rassidakis, AN
    Kanavaros, P
    Field, JD
    Halazonetis, T
    Kittas, C
    ANTICANCER RESEARCH, 1999, 19 (1A) : 579 - 587
  • [50] An MDM2 inhibitor achieves synergistic cytotoxic effects with adenoviruses lacking E1B55kDa gene on mesothelioma with the wild-type p53 through augmenting NFI expression
    Thao Thi Thanh Nguyen
    Shingyoji, Masato
    Hanazono, Michiko
    Zhong, Boya
    Morinaga, Takao
    Tada, Yuji
    Shimada, Hideaki
    Hiroshima, Kenzo
    Tagawa, Masatoshi
    CELL DEATH & DISEASE, 2021, 12 (07)
12345